Generic drug
Carmustine price, strengths & recalls
Carmustine has no weekly pharmacy acquisition cost. 11 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on October 29, 2026.
GenericCarmustine price by strength
What pharmacies pay for each strength and form this week, for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 100 mg injection | Not priced this week | |||
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Carmustine
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use carmustine for injection, USP safely and effectively. See full prescribing information for carmustine for injection, USP.Carmustine for injection, USP, for intravenous useInitial U.S. Approval: 1977
WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY
Myelosuppression
Carmustine for injection, USP causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections. [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1)]. Do not administer a repeat course of carmustine for injection, USP until blood counts recover.
Pulmonary Toxicity
Carmustine for injection, USP causes dose-related pulmonary toxicity. Patients receiving greater than 1400 mg/m2cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in childhood [see Adverse Reactions (6) and Use in Specific Populations (8.4)].
WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY
See full prescribing information for complete boxed warning
Suppression of marrow function, notably thrombocytopenia and leukopenia, is the most common and severe of the toxic effects of carmustine for injection, USP. Monitor blood counts. (5, 6).
Pulmonary toxicity from carmustine for injection, USP appears to be dose related. Patients receiving greater than 1400 mg/m2cumulative dose are at significantly higher risk than those receiving less (5, 6).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA017422 · Avet Lifesciences
- First approved
- March 7, 1977 (49 years ago)
- Latest approved change
- April 30, 2021
- Approved label
- PDF, Mar 27, 2017
- Generic makers
- 8 approved generic applications on the market
Carmustine questions
Is carmustine in shortage?
No shortage is reported for carmustine right now. We check the national shortage list every day.
Has carmustine been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the carmustine label last change?
The official label was last updated on October 29, 2026 (version 12). See what changed.
Talk about carmustine
No comments yet. Questions, tips, what worked for you - start the conversation.